For research use only
| Cat No. | ABC-TC498S |
| Product Type | Human Nerve Tumors Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Glioblastoma |
| Product Code | LN 229; LN229; LNT-229 |
LN-229 is a human glioblastoma line with TP53 mutation, chromosomal instability, used as a model for glioblastoma biology and therapy resistance.
LN-229 is a human glioblastoma cell line established in 1979 from a right frontal parieto-occipital glioblastoma tumor tissue of a 60-year-old European female patient. This epithelial-like cell line grows under adherent culture properties with a doubling time of approximately 31 hours. Karyotype analysis reveals a hyperdiploid chromosomal complement with notable chromosomal instability, including multiple copies of chromosomes 12 and 19. Molecular characterization identifies a TP53 mutation (CCT→CTT transition at codon 98) and homozygous deletions of tumor suppressors p16 and p14ARF, despite retaining wild-type PTEN. LN-229 demonstrates tumorigenicity in nude mouse models, forming subcutaneous tumors upon implantation. These genetic and functional characteristics make LN-229 a relevant preclinical model for glioblastoma biology and treatment resistance.
| Product Code | LN 229; LN229; LNT-229 |
| Species | Human |
| Cat.No | ABC-TC498S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Glioblastoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
LN-229 cells are a widely utilized model in glioblastoma research, particularly for investigating the molecular mechanism under tumor proliferation, genomic instability and therapeutic resistance. The presence of a mutant TP53, deletions in cell cycle regulators, and intact PTEN function provide a representative genetic background for studying key signaling pathways in gliomagenesis. Furthermore, LN-229 is frequently used in the development of advanced radiotherapy strategies. Its use in both basic neuroscience and translational oncology underscores its value in identifying and validating novel therapeutic targets and improving treatment modalities for high-grade gliomas.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
